Skip to main content

Sofinnova Partners — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

148
Companies
$6.3B
Total invested
$48.1M
Avg. check
20
Industries
Biotechnology 18Health Care 11Pharmaceutical 8Medical 7Therapeutics 7Life Science 6+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 148
Prometheus Materials
November 2024

Prometheus Materials develops bio-cement with zero carbon emissions to reduce the global CO2 emissions.

Advanced Materials · Boulder$10.0M Grant
Inotrem
November 2023

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.

Biotechnology · ParisVenture - Series Unknown
AAVantgarde Bio
November 2025

AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.

Biotechnology · Milano$141.0M Series B
HotSpot Therapeutics
November 2021

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

Biopharma · Boston$100.0M Series C
Nitrase Therapeutics
November 2021

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Biotechnology · Jackson$7.0M Series A
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Synthace
November 2021

Synthace is a SaaS Life Sciences R&D Digital Experiment Platform.

Biotechnology · London$35.0M Series C
T-Therapeutics
November 2025

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.

Biotechnology · Cambridge$32.0M Series A
Qorium
November 2025

Real Leather, Reinvented

Biotechnology · Maastricht$25.4M Series A
myTomorrows
November 2025

myTomorrows is a global platform that connects patients with unmet medical needs to treatments in development around the world.

Clinical Trials · Amsterdam$29.0M Private Equity
IOmx Therapeutics
October 2021

iOmx Therapeutics focuses on the development of cancer immunotherapy treatments.

Biopharma · Munich$75.4M Series B
Sphere Bio
October 2021

Sphere Bio specializes in tools for single cell analysis and isolation, facilitating discovery in the biotech field.

Biotechnology · Cambridge$41.4M Venture - Series Unknown
l'école
October 2023

l'école AI is a computer vision-focused development platform.

Artificial Intelligence (AI) · New York$3.0M Seed
Mablink Bioscience
October 2022

Mablink Bioscience is a biotechnology company.

Biotechnology · Lyon$30.1M Series A
Bon Vivant
February 2026

A French biotechnology company that uses precision fermentation to produce real dairy products, accessible to everyone.

Biotechnology · Lyon$29.4M Series A
Muna Therapeutics
January 2026

Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Biopharma · Copenhagen$1.0M Grant
ProQR Therapeutics
January 2026

ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.

Biotechnology · Leiden$9.2M Grant
BrightHeart
January 2026

BrightHeart is a medical technology startup that is developing artificial intelligence software.

Health Care · Paris$12.8M Series A
Mediar Therapeutics
January 2026

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

Biotechnology · Cambridge$76.0M Series B
DISCO Pharmaceuticals
December 2025

DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.

Manufacturing · Cologne$42.3M Seed
Excelsior Sciences
December 2025

Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.

Artificial Intelligence (AI) · New York$70.0M Series A
AFYREN
October 2025

AFYREN develop innovation in biotechnologies for the valorization of non-food biomass and in respect of the environment.

Biotechnology · Saint-beauzire$26.8M Post Ipo Equity
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
Elevara Medicine
October 2025

Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.

Biotechnology · London$70.0M Series A

Where Sofinnova Partners invests

Biotechnology18
Health Care11
Pharmaceutical8
Medical7
Therapeutics7
Life Science6

About Sofinnova Partners's portfolio

How many companies has Sofinnova Partners invested in?

Sofinnova Partners has invested in 148 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Sofinnova Partners invest in?

Sofinnova Partners's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 20 different industry categories.

What is Sofinnova Partners's largest investment?

Among tracked funding rounds, Hemab received $157.0M in a Series C round. Sofinnova Partners's total known invested capital is $6.3B.

What is the average investment size for Sofinnova Partners?

Sofinnova Partners's average investment size is $48.1M across its portfolio of 148 companies.

What are Sofinnova Partners's most recent investments?

Recent Sofinnova Partners portfolio additions include Prometheus Materials, Inotrem, AAVantgarde Bio, HotSpot Therapeutics, Nitrase Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 148 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →